^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Neuroblastoma
    Drug:Unituxin (dinutuximab) (GD2 ganglioside inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    09/29/2020
    Excerpt:
    Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    United Therapeutics Press Release
    Title:

    Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma

    Excerpt:
    United Therapeutics Corporation (NASDAQ: UTHR) announced...Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients...